Replies to post #173549 on Biotech Values

[DewDiligence]

From ABBV CC: Dropout rate in TURQUOISE-2, where 100% of patients had cirrhosis, was only 2%! (GILD has not yet furnished any data on cirrhotic patients from the ‘ION’ studies.)

[genisi]

Only not 'so perfect' thing is in PEARL-IV GT1a "Virologic relapse or breakthrough was noted in 8 percent of patients receiving the regimen without ribavirin and 2 percent of patients receiving the regimen with ribavirin."